



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Ebdrup et al.

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: August 8, 2001

Examiner: To be assigned

For: Novel Process

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:


1. U.S. Patent 5,459,138;
2. WO 99/03861; and
3. WO 97/26265.

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of

record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed on filing date of application. Therefore, no fee is due.

Respectfully submitted,



Date: August 8, 2001

Peter J. Waibel, Reg. No. 43,228  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



23650

PATENT TRADEMARK OFFICE